Steven Joniau mainly investigates Prostate cancer, Surgery, Internal medicine, Prostatectomy and Oncology. His Prostate cancer research integrates issues from Radiation therapy and Urology. His Surgery study incorporates themes from Nephrectomy, Evidence-based medicine, Kidney cancer and Intensive care medicine.
The study incorporates disciplines such as Gynecology and Genetic association in addition to Internal medicine. The various areas that Steven Joniau examines in his Prostatectomy study include Prostate-specific antigen, Randomized controlled trial, Cohort and Watchful waiting. His Oncology study integrates concerns from other disciplines, such as Hormonal therapy, Risk groups, Disease and Docetaxel.
His scientific interests lie mostly in Prostate cancer, Internal medicine, Oncology, Prostatectomy and Urology. His research integrates issues of Surgery, Radiation therapy, Radiology and Lymph node in his study of Prostate cancer. His research brings together the fields of Cystectomy and Surgery.
His research combines Bladder cancer and Oncology. His study in Prostatectomy is interdisciplinary in nature, drawing from both Prostate-specific antigen, Androgen deprivation therapy and Proportional hazards model. His research in Urology intersects with topics in Stage and Biopsy.
Steven Joniau mostly deals with Prostate cancer, Prostatectomy, Internal medicine, Oncology and Urology. Steven Joniau is interested in Androgen deprivation therapy, which is a field of Prostate cancer. His Prostatectomy research incorporates elements of Nomogram and Cohort.
His Oncology research includes themes of Cancer, Metastasis and MEDLINE. Within one scientific family, Steven Joniau focuses on topics pertaining to Bladder cancer under Urology, and may sometimes address concerns connected to Resection and Immunotherapy. His Lymph node study incorporates themes from Radiology and Dissection.
The scientist’s investigation covers issues in Prostate cancer, Prostatectomy, Internal medicine, Oncology and Urology. His primary area of study in Prostate cancer is in the field of Androgen deprivation therapy. His Prostatectomy research is multidisciplinary, relying on both Salvage therapy, Surgery, Retrospective cohort study and Hazard ratio.
His work carried out in the field of Surgery brings together such families of science as Cancer control and Retropubic radical prostatectomy. His Internal medicine research incorporates themes from DNA repair and Surgical excision. His Oncology research is multidisciplinary, incorporating perspectives in Treatment options, Castration resistant, Metastasis and MEDLINE.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
EAU guidelines on prostate cancer
Axel Heidenreich;Gunnar Aus;Michel Bolla;Steven Joniau.
European Urology (2001)
EAU–ESTRO–SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet;Joaquim Bellmunt;Michel Bolla;Erik Briers.
European Urology (2017)
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
Axel Heidenreich;Patrick J. Bastian;Joaquim Bellmunt;Michel Bolla.
European Urology (2014)
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
Axel Heidenreich;Joaquim Bellmunt;Michel Bolla;Steven Joniau.
European Urology (2011)
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer ☆
Nicolas Mottet;Joaquim Bellmunt;Michel Bolla;Steven Joniau.
European Urology (2011)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
Philip Cornford;Joaquim Bellmunt;Michel Bolla;Erik Briers.
European Urology (2017)
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Piet Ost;Dries Reynders;Karel Decaestecker;Valérie Fonteyne.
Journal of Clinical Oncology (2017)
Guidelines on Prostate Cancer
A. Heidenreich;J. Bellmunt;M. Bolla;S. Joniau.
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
Fredrick R. Schumacher;Ali Amin Al Olama;Sonja I. Berndt;Sara Benlloch.
Nature Genetics (2018)
Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer
Johannes V. Swinnen;Tania Roskams;Steven Joniau;Hein Van Poppel.
International Journal of Cancer (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: